Timing of sodium-glucose cotransporter 2 inhibitor initiation and post-discharge outcomes in acute heart failure with diabetes: A population-based cohort study

被引：1
|
作者：
Wu, Che-Yuan [1 ,2 ]
Shah, Baiju R. [3 ,4 ,5 ]
Sharma, Abhinav [6 ,7 ]
Sheng, Yiru [3 ]
Liu, Peter P. [8 ]
Kopp, Alexander [3 ]
Saskin, Refik [3 ]
Edwards, Jodi D. [8 ,9 ,10 ]
Swardfager, Walter [1 ,2 ,11 ]
机构：
[1] Univ Toronto, Dept Pharmacol & Toxicol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada
[2] Sunnybrook Res Inst, Dr Sandra Black Ctr Brain Resilience & Recovery, Hurvitz Brain Sci Program, Toronto, ON, Canada
[3] ICES, Toronto, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Dept Med, Div Endocrinol, Toronto, ON, Canada
[5] Univ Toronto, Dept Med, Toronto, ON, Canada
[6] McGill Univ, Hlth Ctr, Div Cardiol, Montreal, PQ, Canada
[7] McGill Univ, Hlth Ctr, DREAM CV Lab, Montreal, PQ, Canada
[8] Univ Ottawa, Heart Inst, Ottawa, ON, Canada
[9] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada
[10] ICES UOttawa, Ottawa, ON, Canada
[11] KITE Univ Hlth Network Toronto Rehabil Inst, Toronto, ON, Canada
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2025年 / 27卷 / 02期
基金：
加拿大健康研究院;
关键词：
Acute heart failure; Diabetes; SGLT2; inhibitor; Pharmacoepidemiology; IMPACT; RISK;
D O I：
10.1002/ejhf.3464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sodium-glucose cotransporter 2 (SGLT2) inhibitors in acute heart failure. image
引用
收藏
页码：307 / 316
页数：10
相关论文
共 50 条
  • [21] Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study
    Hong, Bin
    Bea, Sungho
    Ko, Hwa Yeon
    Kim, Woo Jung
    Cho, Young Min
    Shin, Ju-Young
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (10) : 1319 - 1329
  • [22] Comment on 'sodium-glucose cotransporter 2 inhibitors and the risk of venous thromboembolism: A population-based cohort study'
    Lai, Shih-Wei
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (01) : 366 - 367
  • [23] Diabetic Ketoacidosis Risk After Initiating an SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitor: A Population-Based Cohort Study
    Fralick, Michael
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 51 - 51
  • [24] DIABETIC KETOACIDOSIS RISK AFTER INITIATING AN SGLT2 (SODIUM-GLUCOSE COTRANSPORTER 2) INHIBITOR: A POPULATION-BASED COHORT STUDY
    Fralick, Michael
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S162 - S162
  • [25] Implementing Sodium-Glucose Cotransporter-2 Inhibitor Therapy for Heart Failure
    Nassif, Michael E.
    Januzzi, James L., Jr.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (19) : 1785 - 1787
  • [26] Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study
    Fu, Edouard L. L.
    D'Andrea, Elvira
    Wexler, Deborah J.
    Patorno, Elisabetta
    Paik, Julie M.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (05): : 592 - 601
  • [27] Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure
    Choday, Silpa
    Ravi, Niriksha
    Parisapogu, Anusha
    Ojinna, Blessing T.
    Sherpa, Mingma L.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (02)
  • [28] SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND REDUCED RISK OF LIVER CANCER IN PEOPLE WITH TYPE 2 DIABETES: A POPULATION-BASED COHORT STUDY
    Huang, Pin-Chia
    Ma, Kevin Sheng-Kai
    HEPATOLOGY, 2023, 78 : S1925 - S1926
  • [29] Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study
    Eroglu, Talip E.
    Coronel, Ruben
    Souverein, Patrick C.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (04) : 289 - 295
  • [30] Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes A Population-Based Cohort Study
    Fralick, Michael
    Chen, Sarah K.
    Patorno, Elisabetta
    Kim, Seoyoung C.
    ANNALS OF INTERNAL MEDICINE, 2020, 172 (03) : 186 - +
12345